- Home
- LNKB vs FDMT Comparison
LNKB vs FDMT Comparison
Compare LNKB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- FDMT
- Stock Information
- Founded
- LNKB 2018
- FDMT 2013
- Country
- LNKB United States
- FDMT United States
- Employees
- LNKB N/A
- FDMT N/A
- Industry
- LNKB
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- FDMT Health Care
- Exchange
- LNKB Nasdaq
- FDMT Nasdaq
- Market Cap
- LNKB 256.4M
- FDMT 207.1M
- IPO Year
- LNKB N/A
- FDMT 2020
- Fundamental
- Price
- LNKB $6.66
- FDMT $4.13
- Analyst Decision
- LNKB Strong Buy
- FDMT Buy
- Analyst Count
- LNKB 1
- FDMT 10
- Target Price
- LNKB $9.00
- FDMT $32.33
- AVG Volume (30 Days)
- LNKB 41.0K
- FDMT 449.2K
- Earning Date
- LNKB 07-28-2025
- FDMT 08-07-2025
- Dividend Yield
- LNKB 4.50%
- FDMT N/A
- EPS Growth
- LNKB N/A
- FDMT N/A
- EPS
- LNKB 0.97
- FDMT N/A
- Revenue
- LNKB $120,786,000.00
- FDMT $23,000.00
- Revenue This Year
- LNKB $21.23
- FDMT $13,048.65
- Revenue Next Year
- LNKB N/A
- FDMT N/A
- P/E Ratio
- LNKB $6.88
- FDMT N/A
- Revenue Growth
- LNKB 135.60
- FDMT N/A
- 52 Week Low
- LNKB $5.86
- FDMT $2.24
- 52 Week High
- LNKB $7.98
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- LNKB 40.55
- FDMT 54.45
- Support Level
- LNKB $6.66
- FDMT $4.21
- Resistance Level
- LNKB $7.23
- FDMT $4.62
- Average True Range (ATR)
- LNKB 0.18
- FDMT 0.30
- MACD
- LNKB -0.03
- FDMT -0.02
- Stochastic Oscillator
- LNKB 8.06
- FDMT 37.42
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.